Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 4 | 2020 | 84 | 2.580 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 18 | 2.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2019 | 14 | 1.790 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 252 | 1.260 |
Why?
|
| Models, Statistical | 4 | 2018 | 164 | 1.130 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 32 | 1.030 |
Why?
|
| Orthopedic Nursing | 2 | 2020 | 4 | 0.940 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 73 | 0.900 |
Why?
|
| Preoperative Care | 2 | 2020 | 110 | 0.870 |
Why?
|
| Neoplasms | 4 | 2018 | 612 | 0.870 |
Why?
|
| Perception | 2 | 2020 | 92 | 0.860 |
Why?
|
| Patient Discharge | 2 | 2019 | 169 | 0.780 |
Why?
|
| Treatment Outcome | 7 | 2020 | 3108 | 0.760 |
Why?
|
| Research Design | 4 | 2019 | 286 | 0.740 |
Why?
|
| Nurses | 1 | 2020 | 14 | 0.730 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 15 | 0.700 |
Why?
|
| Tretinoin | 1 | 2019 | 34 | 0.700 |
Why?
|
| Humans | 42 | 2021 | 29213 | 0.690 |
Why?
|
| Statistics as Topic | 1 | 2018 | 107 | 0.630 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 153 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 196 | 0.620 |
Why?
|
| Medulloblastoma | 1 | 2017 | 7 | 0.600 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 466 | 0.600 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 11 | 0.600 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 546 | 0.590 |
Why?
|
| Maximum Tolerated Dose | 3 | 2018 | 56 | 0.580 |
Why?
|
| Vaginal Smears | 2 | 2014 | 9 | 0.570 |
Why?
|
| Medical Records | 2 | 2013 | 68 | 0.550 |
Why?
|
| Female | 28 | 2020 | 18236 | 0.490 |
Why?
|
| Social Work | 1 | 2014 | 6 | 0.480 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 83 | 0.470 |
Why?
|
| Young Adult | 10 | 2018 | 2413 | 0.460 |
Why?
|
| Kentucky | 5 | 2015 | 15 | 0.440 |
Why?
|
| Aging | 4 | 2018 | 881 | 0.430 |
Why?
|
| Computer Simulation | 4 | 2018 | 211 | 0.420 |
Why?
|
| Lip | 3 | 2017 | 8 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 156 | 0.410 |
Why?
|
| Mass Screening | 1 | 2013 | 225 | 0.410 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 208 | 0.400 |
Why?
|
| Male | 23 | 2020 | 17872 | 0.390 |
Why?
|
| Adult | 17 | 2018 | 8466 | 0.390 |
Why?
|
| Patient Compliance | 1 | 2012 | 212 | 0.390 |
Why?
|
| Postural Balance | 2 | 2018 | 160 | 0.380 |
Why?
|
| Middle Aged | 18 | 2018 | 10868 | 0.380 |
Why?
|
| Food Supply | 2 | 2011 | 54 | 0.370 |
Why?
|
| Adolescent | 9 | 2018 | 3265 | 0.350 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 14 | 0.320 |
Why?
|
| Voice Quality | 2 | 2018 | 6 | 0.320 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 11 | 0.310 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 116 | 0.300 |
Why?
|
| Aged | 14 | 2018 | 9510 | 0.300 |
Why?
|
| Guideline Adherence | 2 | 2014 | 111 | 0.290 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 394 | 0.280 |
Why?
|
| Doxorubicin | 2 | 2017 | 55 | 0.280 |
Why?
|
| Vibration | 2 | 2015 | 10 | 0.280 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 667 | 0.280 |
Why?
|
| Appalachian Region | 3 | 2015 | 16 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 142 | 0.260 |
Why?
|
| Head and Neck Neoplasms | 2 | 2017 | 117 | 0.250 |
Why?
|
| Touch Perception | 1 | 2014 | 2 | 0.250 |
Why?
|
| Postoperative Complications | 2 | 2021 | 670 | 0.240 |
Why?
|
| Papillomavirus Infections | 2 | 2015 | 52 | 0.240 |
Why?
|
| Referral and Consultation | 2 | 2017 | 113 | 0.240 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 7 | 0.240 |
Why?
|
| Sirolimus | 1 | 2013 | 35 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 641 | 0.240 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.230 |
Why?
|
| Gamma Rays | 1 | 2013 | 24 | 0.230 |
Why?
|
| Treatment Failure | 1 | 2013 | 159 | 0.230 |
Why?
|
| Radiation Dosage | 1 | 2013 | 72 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Estradiol | 1 | 2013 | 118 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 327 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Quality of Life | 2 | 2019 | 819 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Nutritional Status | 1 | 2013 | 68 | 0.220 |
Why?
|
| Age Factors | 4 | 2018 | 1110 | 0.210 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 90 | 0.210 |
Why?
|
| Vitamin D | 1 | 2013 | 173 | 0.200 |
Why?
|
| Electric Stimulation Therapy | 1 | 2021 | 18 | 0.200 |
Why?
|
| Muscle Weakness | 1 | 2021 | 39 | 0.190 |
Why?
|
| Quadriceps Muscle | 1 | 2021 | 31 | 0.190 |
Why?
|
| Knee Injuries | 1 | 2021 | 39 | 0.190 |
Why?
|
| Geography | 1 | 2010 | 34 | 0.190 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 25 | 0.190 |
Why?
|
| Infant | 3 | 2018 | 973 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2013 | 322 | 0.180 |
Why?
|
| Child, Preschool | 3 | 2018 | 1168 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2020 | 142 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Interviews as Topic | 1 | 2020 | 249 | 0.180 |
Why?
|
| Vaccination | 1 | 2010 | 123 | 0.170 |
Why?
|
| Behavior Therapy | 1 | 2019 | 92 | 0.170 |
Why?
|
| Algorithms | 2 | 2018 | 463 | 0.170 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 116 | 0.170 |
Why?
|
| Sample Size | 1 | 2018 | 37 | 0.170 |
Why?
|
| Muscle Fatigue | 1 | 2018 | 11 | 0.160 |
Why?
|
| Brain | 2 | 2017 | 930 | 0.160 |
Why?
|
| Voice Disorders | 1 | 2018 | 4 | 0.160 |
Why?
|
| Social Support | 1 | 2019 | 164 | 0.160 |
Why?
|
| Rural Population | 2 | 2015 | 248 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2018 | 603 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2017 | 1694 | 0.160 |
Why?
|
| Shoulder | 1 | 2018 | 41 | 0.160 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2018 | 23 | 0.160 |
Why?
|
| Sports Medicine | 1 | 2018 | 23 | 0.160 |
Why?
|
| Probability | 1 | 2018 | 150 | 0.160 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 177 | 0.160 |
Why?
|
| Voice Training | 1 | 2017 | 1 | 0.160 |
Why?
|
| United States | 4 | 2020 | 3648 | 0.160 |
Why?
|
| Brain Concussion | 1 | 2018 | 60 | 0.160 |
Why?
|
| Cluster Analysis | 2 | 2012 | 128 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2019 | 105 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 2114 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 587 | 0.160 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 6 | 0.160 |
Why?
|
| Laryngectomy | 1 | 2017 | 3 | 0.160 |
Why?
|
| Propranolol | 1 | 2017 | 16 | 0.150 |
Why?
|
| Muscle Contraction | 1 | 2018 | 114 | 0.150 |
Why?
|
| Length of Stay | 1 | 2019 | 294 | 0.150 |
Why?
|
| Vocal Cords | 1 | 2017 | 8 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2018 | 70 | 0.150 |
Why?
|
| Athletic Injuries | 1 | 2018 | 77 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2018 | 3121 | 0.150 |
Why?
|
| Otolaryngology | 1 | 2017 | 17 | 0.150 |
Why?
|
| Child | 3 | 2018 | 2221 | 0.150 |
Why?
|
| Visual Perception | 1 | 2018 | 112 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 56 | 0.150 |
Why?
|
| Face | 1 | 2017 | 25 | 0.150 |
Why?
|
| Myocytes, Cardiac | 1 | 2017 | 87 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 379 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2017 | 28 | 0.150 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 49 | 0.150 |
Why?
|
| Demography | 1 | 2017 | 104 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2017 | 118 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 28 | 0.150 |
Why?
|
| Sensation | 1 | 2017 | 53 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2017 | 99 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2018 | 143 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 172 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 93 | 0.140 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 494 | 0.140 |
Why?
|
| Auditory Threshold | 1 | 2015 | 2 | 0.140 |
Why?
|
| Mesna | 1 | 2015 | 3 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Protective Agents | 1 | 2015 | 4 | 0.130 |
Why?
|
| SEER Program | 1 | 2015 | 33 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 13 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2015 | 45 | 0.130 |
Why?
|
| Survival Rate | 3 | 2018 | 795 | 0.130 |
Why?
|
| Carboplatin | 1 | 2015 | 40 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 18 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2015 | 50 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 709 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 46 | 0.130 |
Why?
|
| Meningioma | 1 | 2015 | 51 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2015 | 53 | 0.130 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 36 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 285 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 200 | 0.120 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 3 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1365 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2013 | 41 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3726 | 0.110 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 105 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2013 | 175 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 384 | 0.110 |
Why?
|
| Hospitals, Public | 1 | 2012 | 5 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2014 | 114 | 0.110 |
Why?
|
| Time Factors | 1 | 2018 | 2003 | 0.110 |
Why?
|
| Rural Health Services | 1 | 2012 | 27 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 64 | 0.100 |
Why?
|
| Restaurants | 2 | 2011 | 7 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1382 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 142 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2018 | 860 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 912 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2017 | 478 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 864 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 281 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 401 | 0.080 |
Why?
|
| Comorbidity | 1 | 2018 | 546 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2018 | 119 | 0.070 |
Why?
|
| Risk Factors | 2 | 2018 | 3547 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 250 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2018 | 440 | 0.070 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 26 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 788 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 35 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 89 | 0.060 |
Why?
|
| Micronutrients | 1 | 2013 | 15 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 167 | 0.050 |
Why?
|
| Urban Population | 1 | 2013 | 79 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 2027 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2013 | 448 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1424 | 0.050 |
Why?
|
| Food Industry | 1 | 2011 | 8 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 18 | 0.050 |
Why?
|
| South Carolina | 1 | 2011 | 29 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 337 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2012 | 126 | 0.050 |
Why?
|
| Logistic Models | 1 | 2013 | 729 | 0.050 |
Why?
|
| Population Density | 1 | 2010 | 6 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2010 | 39 | 0.050 |
Why?
|
| Prevalence | 1 | 2013 | 907 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2021 | 139 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 163 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2013 | 867 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2019 | 165 | 0.040 |
Why?
|
| Proprioception | 1 | 2018 | 5 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 19 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 51 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 64 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 38 | 0.040 |
Why?
|
| Aldehydes | 1 | 2017 | 4 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 34 | 0.040 |
Why?
|
| Athletes | 1 | 2018 | 65 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 47 | 0.040 |
Why?
|
| Proteome | 1 | 2017 | 34 | 0.040 |
Why?
|
| Stroboscopy | 1 | 2017 | 1 | 0.040 |
Why?
|
| Speech Disorders | 1 | 2017 | 6 | 0.040 |
Why?
|
| Speech | 1 | 2017 | 8 | 0.040 |
Why?
|
| Speech Acoustics | 1 | 2017 | 4 | 0.040 |
Why?
|
| Pulmonary Ventilation | 1 | 2017 | 11 | 0.040 |
Why?
|
| Kinetics | 1 | 2017 | 205 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 375 | 0.040 |
Why?
|
| Larynx | 1 | 2017 | 19 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 114 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 156 | 0.040 |
Why?
|
| Proteomics | 1 | 2017 | 92 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2017 | 74 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 55 | 0.040 |
Why?
|
| Fever | 1 | 2017 | 56 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 333 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 189 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 525 | 0.040 |
Why?
|
| Auditory Perception | 1 | 2017 | 80 | 0.040 |
Why?
|
| Shoulder Joint | 1 | 2018 | 123 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 726 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 188 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 38 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 84 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 315 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 724 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 80 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 20 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 78 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 711 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 76 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 95 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 11 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2015 | 24 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2015 | 32 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 113 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 467 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 464 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 235 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 241 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 981 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 437 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 320 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 280 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 1363 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 226 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2017 | 807 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 231 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1123 | 0.030 |
Why?
|
| Mice | 1 | 2017 | 2372 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2015 | 390 | 0.030 |
Why?
|
| African Americans | 1 | 2015 | 1373 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7302 | 0.020 |
Why?
|